
Bipolar Disorder

Kostas N. Fountoulakis

Bipolar Disorder

An Evidence-Based Guide
to Manic Depression

 Springer

Kostas N. Fountoulakis
Division of Neurosciences
3rd Department of Psychiatry
Aristotle University of Thessaloniki
School of Medicine
Thessaloniki
Greece

ISBN 978-3-642-37215-5 ISBN 978-3-642-37216-2 (eBook)
DOI 10.1007/978-3-642-37216-2
Springer Heidelberg New York Dordrecht London

Library of Congress Control Number: 2014956965

© Springer-Verlag Berlin Heidelberg 2015

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

*To Katerina
My sons Nickolas and Ioannis
My parents Nick and Olga and parents-in-
law Ioannis and Zoumboulia
For without their enduring support, this book
would not have been possible to author*

Foreword

During the latter part of the twentieth century, manic depression emerged as a new focus of research that over time came to achieve an equal status with schizophrenia and depression among mental health professionals. Indeed, because of its complexity and high cost and its flamboyant symptomatology, it now tends to enjoy a privileged status, especially in the minds of those working in the arts and sciences.


Manic depression has a number of impressive characteristics. First, it has become almost fashionable to admit that one suffers from this mental disease. Second, there is a widespread belief that it is strongly correlated with creativity. Many famous people announce publicly that they suffer from it, while historical and biographical data suggest that other renowned personalities from the past have been afflicted with the illness. Third, manic depression is one of the very few medical conditions that respond to treatment with a single simple natural element: lithium. This is extraordinary, and the way in which this happens is unique in medicine.

This book is a single-authored work. This is rather unusual today, when multi-authored books are the rule. An extremely large amount of work is needed to accomplish such a task, especially when the purpose is to systematically review the literature and try to follow the rules of evidence-based medicine to the extent that the literature permits it. The result, however, is a comprehensive, solid book and not a heterogeneous compilation of book chapters.

The various chapters of this book address distinct aspects of the disease, from traditional ones such as the historical perspective to modern approaches like staging. Especially the chapter on biological therapies utilizes a precise methodology in the collecting and ranking of data and agents and thereby provides the reader with the state of the art in a comprehensive way which can rarely be found in a book. I strongly believe that the book will satisfy the most discriminating of readers, including both those seeking an update on a specific aspect of the illness and those whose need is a comprehensive reference.

I have no doubt that this book will have a significant impact on the field and will constitute a very important resource for teaching, training and research and provide guidance for everyday clinical practice.

The hope is that it will also help to upgrade the status of bipolar disorder on the agenda of policy makers and promote awareness of the illness so that the needed resources are allocated both for further research in the field and for the targeted treatment and care of patients and their families.



Gothenburg, Sweden
October 2014

Arvid Carlsson
Nobel laureate in medicine 2000
Emeritus Professor of Pharmacology
Sahlgrenska Academy,
University of Gothenburg,
Gothenburg,
Sweden

Contents

1 Historical Perspective	1
1.1 Antiquity	1
1.2 Middle Ages	6
1.3 Modern Era	9
References	23
2 Clinical Description	27
2.1 Normal Emotions, Neurobiology and Ethological Considerations	27
2.2 The Conceptualization of Bipolar Disorder	31
2.3 Bipolar Depression	35
2.4 Mania	44
2.5 Hypomania	51
2.6 Mixed States	52
2.7 Psychotic Features	56
2.8 Other Clinical Issues	59
2.9 The Subjective Experience of Manic–Depressive Patients	60
2.10 List and Definitions of Symptoms and Signs	62
2.10.1 Mood	62
2.10.2 Psychomotor Disorder	64
2.10.3 Neurocognitive Disorder	65
2.10.4 Thought Disorder	66
2.10.5 Psychotic Features	67
2.10.6 Somatic and Neurovegetative Symptoms	68
2.10.7 Behavioural Disorder	70
References	70
3 Long-Term Course	81
3.1 Predominant Polarity	81
3.2 Seasonality	84
3.3 Rapid Cycling	87
References	96

4 Neurocognitive Functioning in Bipolar Disorder:	
A Comprehensive Review of Recent Data	109
4.1 General Neurocognitive Functioning and Intelligence Quotient (IQ)	110
4.2 Psychomotor and Mental Speed	113
4.3 Attention	114
4.4 Learning and Memory	115
4.5 Verbal Skills	117
4.6 Visuospatial Skills	118
4.7 Executive Function	118
4.8 Social Cognition and Theory of Mind (ToM)	120
4.8.1 ToM	121
4.8.2 Emotion Processing	121
4.8.3 Emotional Decision-Making	122
4.8.4 Reviews and Meta-analyses	122
4.9 Clinical Correlations	123
4.9.1 The Effect of Medication	123
4.9.2 The Effect of Psychotic Symptoms	126
4.9.3 The Effect of Mood Symptoms	127
4.9.4 The Effect of Age and Age at Onset and Personal Psychiatric History	129
4.9.5 The Role of Other Clinical Factors	130
4.10 BD-II	131
4.11 Long-Term Development of the Neurocognitive Deficit	133
4.12 Awareness of the Neurocognitive Deficit	136
4.13 Gender and the Neurocognitive Deficit	137
4.14 The Neurocognitive Deficit as an Endophenotype for BD	137
4.14.1 Twin Studies	138
4.14.2 Studies on First-Degree Relatives	138
4.14.3 Studies on Mixed Samples of Relatives	139
4.14.4 Reviews and Meta-analyses	139
References	142
5 The Role of Temperament	163
5.1 Historical Perspective	163
References	174
6 The Bipolar Spectrum	181
References	186
7 Schizoaffective Disorder	189
References	193
8 Personality Disorders (Narcissistic, Antisocial, Borderline)	197
References	202

9	Alcohol and Substance Use in BD Patients	205
9.1	Epidemiology	205
9.1.1	Epidemiology of Alcohol Use Disorder	206
9.1.2	Epidemiology of Cannabis Use Disorder	207
9.1.3	Epidemiology of Gambling.	207
9.1.4	Epidemiology of Methadone.	207
9.1.5	Epidemiology of Cocaine	207
9.1.6	Epidemiology of Opioids	208
9.1.7	Epidemiology of Smoking	208
9.2	Etiopathogenesis of SUD in BD	208
9.2.1	General Causative Factors and Mechanisms.	208
9.2.2	Neurobiology	209
9.3	Clinical Issues	210
9.3.1	Clinical Issues Related to Alcohol Use.	211
9.3.2	Clinical Issues Related to Cannabis Use.	212
9.3.3	Clinical Issues Related to Cocaine Use	213
9.3.4	Clinical Issues Related to Opioid Use	213
9.3.5	Clinical Issues Related to Nicotine Use and Smoking	213
9.3.6	Substance Use and Neurocognitive Disorder	214
9.3.7	Comorbidity	214
9.3.8	Disability.	214
9.3.9	Suicidality	214
9.4	Legal Issues.	215
9.5	Treatment	215
	References	216
10	Comorbidity	225
10.1	Psychiatric Comorbidity	226
10.1.1	Comorbid Anxiety.	230
10.1.2	Comorbid Obsessive–Compulsive Disorder (OCD).	246
10.1.3	Comorbid Attention Deficit Hyperactivity Disorder (ADHD).	250
10.1.4	Comorbid Complicated Grief (CG)	255
10.1.5	Comorbid Eating Disorders.	255
10.1.6	Various Other Comorbid Conditions.	257
10.1.7	Comorbid Psychiatric Disorders and BD-II	260
10.2	Medical Comorbidity	260
10.2.1	General Medical Comorbidity.	260
10.2.2	Metabolic Syndrome and Related Medical Conditions	262
10.2.3	Comorbid Vascular Disease	275
10.2.4	Comorbid Neurological Conditions	277
10.2.5	Infectious Diseases	286
10.2.6	Cancer	290
10.2.7	Endocrinological Disorders.	290

10.2.8	Gastroenterological Disorders.	296
10.2.9	Disorders of the Blood	296
10.2.10	Respiratory System Disorders.	296
10.2.11	Various Comorbid Medical Disorders.	301
10.3	Genetics and Endophenotypes	311
	References	314
11	Classification and Epidemiology.	341
11.1	Classification.	341
11.1.1	General Considerations	341
11.1.2	Contemporary Classification Systems.	342
11.1.3	Contemporary Classification of BD and Related Disorders.	343
11.2	Epidemiology of BD.	347
11.2.1	The Amish Study.	348
11.2.2	The Epidemiological Catchment Area (ECA)	348
11.2.3	The National Comorbidity Survey (NCS).	351
11.2.4	The Cross-National Collaborative Group (CNCG).	351
11.2.5	Zurich Switzerland	352
11.2.6	Shatin, Hong Kong	352
11.2.7	Nottingham, UK	352
11.2.8	The Netherlands Study	352
11.2.9	The Australian Study.	353
11.2.10	The Butajira Study	353
11.2.11	The Merikangas Study	353
11.2.12	Other Smaller Studies	353
11.2.13	Epidemiology of the Bipolar Spectrum.	354
11.2.14	Conclusions on Epidemiology	355
	References	355
12	Disability and Overall Burden Related with Bipolar Disorder	361
12.1	Disability.	361
12.1.1	Overview and Definitions	361
12.1.2	Disability in BD Patients.	362
12.2	Quality of Life	367
12.3	Caregiver and Family Burden.	367
12.3.1	Prevalence of Caregiver Burden	368
12.3.2	Objective Burden.	369
12.3.3	Subjective Burden	370
12.3.4	Influence of Sociodemographic Factors on Caregiver Burden	372
12.3.5	Special Topics Related to Caregiver Burden.	373
12.3.6	Comparison with Burden Caused by Other Disorders	374
12.3.7	Interventions	374
12.3.8	Caregiver Burden and Patient Outcome	375

12.4	Cost	376
12.5	Stigma	378
	References	379
13	Aetiopathogenesis of Bipolar Disorder	389
13.1	Social Theories	389
13.2	Psychological Theories	390
13.2.1	Aggression-Turned-Inward Model	391
13.2.2	Object Loss	391
13.2.3	Loss of Self-Esteem	392
13.2.4	Cognitive Model	392
13.2.5	Learned Helplessness Model	392
13.2.6	Depression and Reinforcement	393
13.3	Neurobiology of BD	393
13.3.1	Neuroanatomy of BD	393
13.3.2	Functional Studies	398
13.3.3	Neurotransmitters and Receptors	400
13.3.4	Genetic Studies	406
	References	408
14	Psychometric and Neuropsychological Assessment	421
14.1	Introduction	421
14.2	Psychometric Tools	422
14.2.1	Depression Rating Scales	422
14.2.2	Mania Rating Scales	425
14.2.3	Anxiety Rating Scales	425
14.2.4	Psychotic Symptoms Rating Scales	427
14.2.5	Disability and General Assessment	428
14.2.6	Temperament and Personality Inventories	429
14.2.7	Adverse Events Scales	430
14.2.8	Substance Use Scales	431
14.2.9	Other Rating Scales	432
14.3	Neuropsychological Tools	432
	References	434
15	Staging of Bipolar Disorder	437
15.1	The Concept of Staging	437
15.2	Staging of BD	438
15.2.1	Clinical Determinants of BD Staging	438
15.2.2	Neurobiological Determinants of BD Staging	441
15.2.3	Treatment Data Supporting the Staging Approach	445
15.3	Existing Models for the Staging of BD	446
15.3.1	The Model of Berk	446
15.3.2	The Model of Kapczinski	449
15.3.3	The Model of Post	449
15.3.4	The Model of Cosci and Fava	450
15.3.5	The Model of Frank	450
15.4	The Future of Staging of BD	451
	References	452

16	Biological Therapies	461
16.1	General Background	461
16.1.1	Lithium	461
16.1.2	Antiepileptics	466
16.1.3	Antipsychotics	469
16.1.4	Antidepressants	469
16.2	Evidence-Based Treatment	470
16.2.1	Acute Mania	472
16.2.2	Acute Bipolar Depression	530
16.2.3	Maintenance Treatment	555
16.2.4	Treatment of Mixed Episodes	581
16.2.5	Treatment of Rapid Cycling Patients	582
16.2.6	Treatment of Special Conditions	584
16.2.7	Cautions for Pharmaceutical Treatment in BD Patients	587
16.2.8	Switching to the Opposite Pole	590
	References	593
17	Psychosocial Treatment and Interventions	627
17.1	General Background	627
17.2	Specific Psychotherapies and Psychosocial Interventions	628
17.2.1	Cognitive-Behavioural Therapy (CBT)	628
17.3	Psychoeducation	629
17.4	Interpersonal and Social Rhythm Therapy (IPSRT)	630
17.5	Family Intervention	631
17.6	Intensive Psychosocial Intervention	632
17.7	Cognitive Remediation and Functional Remediation	633
17.8	Mindfulness-Based Interventions	633
	References	637
18	Treatment Guidelines	643
18.1	Background	643
18.2	List of Existing Guidelines	644
18.3	Critical Review of the Most Important Guidelines	645
18.3.1	American Psychiatric Association Treatment Guidelines for BD	645
18.3.2	The Canadian Network for Mood and Anxiety Treatments and International Society on Bipolar Disorder Guidelines (CANMAT/ISBD)	646
18.3.3	The Texas Medication Algorithm Project (TMAP) for the Treatment of BD	648
18.3.4	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of BD	649
18.3.5	British Association for Psychopharmacology (BAP)	650

18.3.6	The UK National Institute of Clinical Excellence (NICE) Treatment Guidelines for BD	650
18.4	Critical View of Treatment Guidelines for BD	651
	References	654
19	Special Issues	659
19.1	Gender	659
19.2	Suicidality	660
19.3	Paediatric BD	663
19.3.1	Epidemiology of Paediatric BD	664
19.3.2	Clinical Features of Paediatric BD	664
19.3.3	Aetiopathogenesis of Paediatric BD	666
19.3.4	Treatment of Paediatric BD	667
19.4	Geriatric BD	668
19.4.1	Epidemiology of Geriatric BD	668
19.4.2	Clinical Features of Geriatric BD	669
19.4.3	Neurobiology of Geriatric BD	671
19.4.4	Treatment of Geriatric BD	672
	References	673
20	Creativity and the Position of Bipolar Disorder in Popular Culture	685
20.1	Creativity	685
20.1.1	The Concept of Creativity	685
20.1.2	The Philosophical and Journalistic Approach	687
20.1.3	The Scientific Approach	693
20.1.4	Possible Mediating Mechanisms Between Creativity and BD	695
20.1.5	The Effect of Treatment and Other Ethical Considerations	696
20.2	The Place of BD in Popular Culture	697
	References	700
Index	705

Introduction

Since nearly 3,000 years, mood disorders have been described in the medical literature, and the terms mania and melancholia are the oldest in psychiatry and also among the oldest in medicine. Although they are considered to constitute one of the most common group diseases of humanity, accompanied by heavy burden, disability, mortality and cost, only recently the major public health interest focused on them. Since the 1990s, the World Health Organization has ranked them among the most disabling medical conditions and among the most urgent health problems worldwide.

From Hippocrates to Aretaeus of Cappadocia, to Kraepelin, Aubrey Lewis and Sir Martin Roth, to Fred Goodwin, Hagop Akiskal and other prominent researchers, our understanding of bipolar disorder (BD) evolved from an episodic disorder with little disability and good prognosis to a probably developmental, chronic, disabling disease with significant burden, mortality and global cost for the society (Goodwin and Jamison 1990; Aretaeus of Cappadocia 1856; Kraepelin 1921). With the introduction of modern classification systems and the advancement of the evidence-based movement in medicine and psychiatry, our approach is reshaped and our knowledge and data are scrutinized and re-evaluated.

Still many questions remain to be answered. One of them concerns the existence of a spectrum of mood disorders which includes many conditions previously diagnosed as schizophrenia, personality disorder, or neurosis. This implies the presence of a clinical continuum, and it is in sharp contrast to the categorical approach of classification systems. Another question concerns the possible role and place of juvenile mood disorders (Poznanski and Zrull 1970; Puig-Antich 1987; Weller et al. 1995; Carlson and Strober 1978; Akiskal et al. 1985). One of the most cardinal issues is how to reduce overall mortality in general and suicidality in particular, since mood disorders underlie nearly two-thirds of suicide attempts (Isometsa et al. 1994; Luoma et al. 2002; Rihmer et al. 2002; Rihmer 2007), and therefore early identification and correct treatment is important.

Bipolar disorder (BD) was previously called manic–depressive psychosis, and its clinical picture consists of at least one hypomanic, manic, or mixed episode and one or more depressive episodes. Euphoric mania was the classic feature of BD, but today we know that mixed and agitated depression or dysphoric manic states are more prevalent. Also, recent data suggest the existence of a spectrum of milder, short-duration and ambulatory mood states that alternate. Comorbidity patterns include high rates of panic, obsessive–compulsive disorder, social phobia, and alcohol and stimulants

abuse. Somatic illness is also highly prevalent, and vascular brain disease might relate to a specific type of late-onset BD. In many ways, the old term ‘manic depression’ seems much more appropriate than the modern ‘bipolar disorder’.

The aetiopathogenesis might include genetic, neurodevelopmental and psychosocial factors with neurobiological factors being predominant. Since antiquity, temperament was considered to constitute a vulnerability factor for the development of mood disorders. During the last few decades, the concept of temperament has been refined and redefined and specific variations, possibly hereditary to a significant degree, have been described (Akiskal and McKinney 1973; Akiskal 1995). Women might be at higher risk, but the specific sex-related factors leading to this increased vulnerability are unknown (Nazroo et al. 1997; Parry 1989).

However, a family environment with parents suffering from overt mood disorders or having personality or temperament features that predispose to mood disorders is often characterized by conflicts, bereavement, divorce and suicide, but often it is also characterized by creativity and openness. This is often the environment where a child with a genetic vulnerability to mood disorders is born and raised. The interaction between adverse life events and genetic vulnerability might further increase the risk for the development of mood disorders (Kendler and Karkowski-Shuman 1997).

More than a century has already passed since Frederik Lange in the late nineteenth century (Lange 1894) used lithium for the first time. Also more than half a century has passed since John Cade used it for the treatment of affective patients (Cade 1949, 1970; Bech 2006) and since Jean Delay and Pierre Deniker used an antipsychotic for the first time most likely in agitated manic patients (Delay and Deniker 1955). Psychopharmacology reshaped the way we view and treat mental disorders, including BD. It ‘medicalized’ psychiatry because one needs to be competent in medicine in order to use medication properly and adequately. It is widely accepted that BD requires prolonged somatic treatment in order to achieve remission of symptomatology and return of functioning. Polypharmacy might be the rule rather than the exception, and this issue requires caution and further research. Psychosocial therapy by skilled clinicians can provide support, combat demoralization, change maladaptive behaviours and improve functioning. It can provide relief and support not only to patients but also to caregivers and families.

It is disappointing that any advances that have occurred in our understanding of BD do not appear to have improved the morbidity and mortality of BD patients and their long-term prognosis to the extent it was anticipated. On the other hand, it is a difficult task for the average clinician to keep abreast of the advances in the field, and it is even more difficult to carry these advances into everyday clinical practice.

The current book aims at carrying these advances from the research literature to the everyday diagnostic and therapeutic practice, in a concise, comprehensive and operationalized way, for the ultimate benefit of the patients and their families.

It is not easy nowadays to write and publish a single-authored book. The challenge was great for me, and I would dare to say that this is the most challenging invitation I have ever received. It took me almost three years to complete the writing, and it was a fascinating journey with hot interactions between my personal clinical experience and research and the literature.

My driving thought was to write a book as much evidence-based as possible. Eventually, this was possible for almost all chapters which were based on an in-depth systematic review of the literature updated through the year 2014. More than 3,700 references are included in the book, and many times this number were the references that were screened and rejected.

The text includes a balanced view of conflicting approaches, but this is not done in a neutral or uncritical manner. The conclusions are evidenced-based, after a critical systematic review of the literature, and only on rare occasions my own clinical perspective or opinion leads to the conclusions.

At this point, I would like to thank two eminent people who guided, assisted and supported me through my journey into the science of psychiatry all these years. I have the pleasure to call them my mentors and the privilege to consider them friends.

It is Hagop S. Akiskal who over the last 15 years has introduced me to and helped me with the modern concepts and understanding of mood disorders, while it is Hans-Jurgen Moeller who has guided me for more than a decade in the difficult pathways of modern psychopharmacology and trusted me with important initiatives in the field. Without their unconditional support, my journey in the international arena of science wouldn't have been possible. Of course, the current book reflects my personal view on the topic of manic depression, and I am the only one to assume full responsibility for the content of the text.

I also would like to thank Professor Arvid Carlsson, Nobel Laureate in Medicine for the year 2000, for accepting to write a prologue for the book. His kind words are a great honour and ethical satisfaction for my efforts, and since I met him for the first time some 10 years ago, his figure serves as an ideal paradigm for my journey through the wandering rocks of science (only to quote his words).

Finally, I would like to thank all my colleagues in my research team through the last 15 years. They worked hard, accepted me and my peculiarities and demands, and together we tried to contribute to the development of the field through the accumulation of evidence. I also want to thank my colleagues in the 3rd Department of Psychiatry for their continuous support and understanding.



Thessaloniki, Greece
10 September 2014

Kostas N. Fountoulakis, MD, PhD

References

- Akiskal HS (1995) Toward a temperament-based approach to depression: implications for neurobiologic research. *Adv Biochem Psychopharmacol* 49:99–112
- Akiskal HS, McKinney WT Jr (1973) Depressive disorders: toward a unified hypothesis. *Science* 182(4107):20–29
- Akiskal HS, Downs J, Jordan P, Watson S, Daugherty D, Pruitt DB (1985) Affective disorders in referred children and younger siblings of manic-depressives. Mode of onset and prospective course. *Arch Gen Psychiatry* 42 (10):996–1003
- Aretaeus of Cappadocia (1856) *The extant works of Aretaeus, the Cappadocian*. Sydenham Society, London
- Bech P (2006) The full story of lithium. A tribute to Mogens Schou (1918–2005). *Psychother Psychosom* 75(5):265–269
- Cade J (1949) Lithium salts in the treatment of psychotic excitement. *Med J Aust* 36:349–352
- Cade J (1970) The story of lithium. In: Ayd F, Blackwell B (eds) *Discoveries in biological psychiatry*. Lippincott, Philadelphia
- Carlson GA, Strober M (1978) Manic-depressive illness in early adolescence. A study of clinical and diagnostic characteristics in six cases. *J Am Acad Child Psychiatry* 17(1):138–153
- Delay J, Deniker P (1955) Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. *J Clin Exp Psychopathol* 16(2):104–112
- Goodwin F, Jamison K (1990) *Manic-depressive illness*. Oxford University Press, New York
- Isometsa E, Henriksson M, Aro H, Heikkinen M, Kuoppasalmi K, Lonnqvist J (1994) Suicide in psychotic major depression. *J Affect Disord* 31(3):187–191
- Kendler KS, Karkowski-Shuman L (1997) Stressful life events and genetic liability to major depression: genetic control of exposure to the environment? *Psychol Med* 27(3):539–547
- Kraepelin E (1921) *Manic-depressive insanity and paranoia*. Livingstone, Edinburgh
- Lange F (1894) *De vigtigste Sindssygdomme (The most important Psychiatric disorders)*. Gyldendal, Copenhagen
- Luoma JB, Martin CE, Pearson JL (2002) Contact with mental health and primary care providers before suicide: a review of the evidence. *Am J Psychiatry* 159(6):909–916
- Nazroo JY, Edwards AC, Brown GW (1997) Gender differences in the onset of depression following a shared life event: a study of couples. *Psychol Med* 27(1):9–19
- Parry BL (1989) Reproductive factors affecting the course of affective illness in women. *Psychiatr Clin North Am* 12(1):207–220
- Poznanski E, Zrull JP (1970) Childhood depression. Clinical characteristics of overtly depressed children. *Arch Gen Psychiatry* 23(1):8–15
- Puig-Antich J (1987) Affective disorders in children and adolescents. In: Meltzer H (ed) *Psychopharmacology: the third generation of progress*. Raven, New York
- Rihmer Z (2007) Suicide risk in mood disorders. *Curr Opin Psychiatry* 20(1):17–22
- Rihmer Z, Belso N, Kiss K (2002) Strategies for suicide prevention. *Curr Opin Psychiatr* 15:83–87
- Weller EB, Weller RA, Fristad MA (1995) Bipolar disorder in children: misdiagnosis, underdiagnosis, and future directions. *J Am Acad Child Adolesc Psychiatry* 34(6):709–714. doi:10.1097/00004583-199506000-00010, S0890-8567(09)63568-1 [pii]